ABBV AbbVie Inc

Price (delayed)

$166.41

Market cap

$293.96B

P/E Ratio

60.96

Dividend/share

$6.06

EPS

$2.73

Enterprise value

$340.53B

AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories. On October 19, 2011, Abbott Laboratories announced its plan to separate ...

Highlights
The debt has declined by 6% year-on-year and by 2.2% since the previous quarter
ABBV's P/E is 117% above its 5-year quarterly average of 28.1 and 50% above its last 4 quarters average of 40.6
The company's net income has shrunk by 59% YoY and by 25% QoQ

Key stats

What are the main financial stats of ABBV
Market
Shares outstanding
1.77B
Market cap
$293.96B
Enterprise value
$340.53B
Valuations
Price to book (P/B)
28.36
Price to sales (P/S)
5.42
EV/EBIT
42.97
EV/EBITDA
20.49
EV/Sales
6.27
Earnings
Revenue
$54.32B
EBIT
$7.92B
EBITDA
$16.62B
Free cash flow
$22.06B
Per share
EPS
$2.73
Free cash flow per share
$12.48
Book value per share
$5.87
Revenue per share
$30.72
TBVPS
$26.48
Balance sheet
Total assets
$134.71B
Total liabilities
$124.31B
Debt
$59.39B
Equity
$10.36B
Working capital
-$4.84B
Liquidity
Debt to equity
5.73
Current ratio
0.87
Quick ratio
0.63
Net debt/EBITDA
2.8
Margins
EBITDA margin
30.6%
Gross margin
62.4%
Net margin
9%
Operating margin
23.5%
Efficiency
Return on assets
3.6%
Return on equity
40%
Return on invested capital
13.2%
Return on capital employed
8.2%
Return on sales
14.6%
Dividend
Dividend yield
3.64%
DPS
$6.06
Payout ratio
222%

ABBV stock price

How has the AbbVie stock price performed over time
Intraday
1.06%
1 week
2.54%
1 month
-7.38%
1 year
3.23%
YTD
7.38%
QTD
-8.62%

Financial performance

How have AbbVie's revenue and profit performed over time
Revenue
$54.32B
Gross profit
$33.9B
Operating income
$12.76B
Net income
$4.86B
Gross margin
62.4%
Net margin
9%
The company's net income has shrunk by 59% YoY and by 25% QoQ
The net margin has dropped by 56% year-on-year and by 24% since the previous quarter
The operating income has contracted by 30% YoY and by 15% from the previous quarter
The operating margin has declined by 25% year-on-year and by 14% since the previous quarter

Growth

What is AbbVie's growth rate over time

Valuation

What is AbbVie stock price valuation
P/E
60.96
P/B
28.36
P/S
5.42
EV/EBIT
42.97
EV/EBITDA
20.49
EV/Sales
6.27
ABBV's P/E is 117% above its 5-year quarterly average of 28.1 and 50% above its last 4 quarters average of 40.6
The EPS has plunged by 59% YoY and by 25% from the previous quarter
AbbVie's equity has decreased by 40% YoY and by 14% from the previous quarter
ABBV's price to book (P/B) is 29% higher than its last 4 quarters average of 22.0
ABBV's P/S is 29% above its 5-year quarterly average of 4.2 and 13% above its last 4 quarters average of 4.8
ABBV's revenue is down by 6% year-on-year

Efficiency

How efficient is AbbVie business performance
AbbVie's return on assets has shrunk by 57% YoY and by 25% QoQ
The ROE has contracted by 46% YoY and by 15% from the previous quarter
The ROS has contracted by 45% YoY and by 18% from the previous quarter
AbbVie's ROIC has decreased by 42% YoY and by 16% from the previous quarter

Dividends

What is ABBV's dividend history
DPS
$6.06
Dividend yield
3.64%
Payout ratio
222%
Recent dividends

Financial health

How did AbbVie financials performed over time
AbbVie's total assets is 8% higher than its total liabilities
The quick ratio has contracted by 11% from the previous quarter and by 9% YoY
ABBV's current ratio is down by 9% since the previous quarter and by 9% year-on-year
The company's debt to equity has surged by 56% YoY and by 14% QoQ
AbbVie's equity has decreased by 40% YoY and by 14% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.